Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)

Recurrent Pericarditis Clinical Trial

Official title:

Impact of CardiolRxTM on Recurrent Pericarditis An Open Label Pilot Study (MAvERIC-Pilot Study)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05494788
• Other study ID #: Cardiol 100-004
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 30, 2022
• Est. completion date: September 15, 2024

Study information

• Verified date: February 2024
• Source: Cardiol Therapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol [CBD] solution) is known to have anti-inflammatory properties, including modulation of inflammasome signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the resolution of pericarditis symptoms, assess improvement in objective measures of disease, and during the extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRxTM.

Description:

Multi-center, open label Pilot Study. Patients who present with recurrent pericarditis will be screened and informed consent obtained. Baseline assessments include the following: Clinical assessment, including vital signs, highest NRS pain score within the past 7 days of Day 1, 12-lead ECG; C-SSRS as well as hematology and blood chemistry and a pregnancy test for women with child-bearing potential. Concomitant medications are recorded and any (S)AEs after informed consent has been obtained. Study treatment will be initiated in the evening of Day 1, after all baseline assessments are completed. Oral administration is as follows: - Initial starting dose (Day 1 p.m. dose to Day 3 a.m. dose): 5 mg/kg of body weight CardiolRxTM - Day 3 p.m. dose to Day 10 a.m. dose: 7.5 mg/kg of body weight CardiolRxTM b.i.d. - Day 10 p.m. dose to end of treatment period: 10.0 mg/kg of body weight CardiolRxTM b.i.d. If the next higher dose after each study drug increase is not tolerated, the dose will be reduced to the previous tolerated dose. Unless contraindicated in the opinion of the investigator, after 8 weeks of treatment, patients will enter an 18-week extension period (EP), in which they continue study treatment while their concomitant medications will be weaned. Follow-up Procedures Every visit (before the next dose increase) the patient will be re-evaluated. This includes ECG monitoring at approximately 5 hours post-morning dose (Tmax) to surveil for deleterious effects on ECG intervals (particularly the QTc interval) and rhythm. Drug titration will be dependent on investigator or designate interrogation of the ECGs and the absence of new, clinically significant abnormalities on those ECGs. Vital signs, concurrent medication and (S)AEs will be recorded at all visits. Blood chemistry including liver function tests, hematology as well as INR assessments will be carried out at selected visits. Final efficacy assessments will take place after 26 weeks of study treatment and include a clinical assessment, vital signs, pain score NRS, a 12-lead ECG, the C-SSRS, as well as laboratory assessments. For patients who do not enter the EP, Final assessments will be done after 8 weeks.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 25
• Est. completion date: September 15, 2024
• Est. primary completion date: June 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female 18 years of age or older

2. Diagnosis of at least two episodes of recurrent pericarditis*,

3. At least 1 day with pericarditis pain =4 on the 11-point Numerical Rating Scale (NRS) within prior 7 days

4. One of;

1. C-Reactive Protein** (CRP) level =1.0 mg/dL within prior 7 days OR

2. Evidence of pericardial inflammation assessed by delayed pericardial hyperenhancement on cardiac magnetic resonance imaging (CMR)

5. Currently receiving non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine and/or corticosteroids (in any combination) for treatment of pericarditis in stable doses

6. Male patients with partners of childbearing potential who have had a vasectomy or are willing to use double barrier contraception methods during the conduct of the study and for 2 months after the last dose of study drug.

7. Women of childbearing potential willing to use an acceptable method of contraception starting with study drug administration and for a minimum of 2 months after study completion. Otherwise, women must be postmenopausal (at least 1 y absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone [FSH] =40 mIU/mL [or = 40 IU/L] if less than 2 y postmenopausal) or be surgically sterile.

• Diagnosis of pericarditis according to the 2015 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Management of Pericardial Diseases (Adler et al. 2015):

At least two of:

1. Pericarditic chest pain

2. Pericardial rub

3. New widespread ST-segment elevation or PR-segment depression according to electrocardiogram (ECG) findings

4. Pericardial effusion (new or worsening)

• Conversion: 1 mg/dL CRP = 10 mg/L hs-CRP

Exclusion Criteria:

1. Diagnosis of pericarditis that is secondary to specific prohibited etiologies, including tuberculosis (TB); neoplastic, purulent, or radiation etiologies; post-thoracic blunt trauma (e.g., motor vehicle accident); myocarditis

2. Estimated glomerular filtration rate (eGFR) <30 mL/min at screening

3. Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN) or ALT or AST >3x ULN plus bilirubin >2x ULN

4. Sepsis, defined as documented bacteremia at the time of screening or other documented active infection

5. Prior history of sustained ventricular arrhythmia

6. History of QT interval prolongation

7. QTc interval > 500 msec

8. Current participation in any research study involving investigational drugs or device

9. Inability or unwillingness to give informed consent

10. Ongoing drug or alcohol abuse

11. On any cannabinoid during the past month

12. Women who are pregnant or breastfeeding

13. Current diagnosis of cancer, with the exception of non-melanoma skin cancer

14. Any factor, which would make it unlikely that the patient can comply with the study procedures

15. Showing suicidal tendency as per the Columbia Suicide Severity Rating Scale (C-SSRS), administered at screening

16. On digoxin and/or type 1 or 3 antiarrhythmics

17. On immunosuppressive therapy with any of the following:

1. Rilonacept

2. Anakinra

3. Canakinumab

4. Methotrexate

5. Azathioprine

6. Cyclosporine

7. Intravenous immune globulin (IVIG)

Related Conditions & MeSH terms

• Pericarditis
• Recurrence
• Recurrent Pericarditis

Intervention

Drug:
• CardiolRx
Pharmaceutically produced Cannabidiol

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	University of Vermont Medical Center	Burlington	Vermont
United States	Cleveland Clinic	Cleveland	Ohio
United States	Minneapolis Heart Institute Foundation	Minneapolis	Minnesota
United States	Virginia Commonwealth University Health	Richmond	Virginia
United States	Mayo Clinic	Rochester	Minnesota
United States	Pima Heart and Vascular Clinical Research	Tucson	Arizona
United States	MedStar Health Research Institute	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Cardiol Therapeutics Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabate Tenas M, Seferovic P, Swedberg K, Tomkowski W; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 7;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318. Epub 2015 Aug 29. No abstract available. — View Citation

Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D, Luis SA, Nicholls SJ, Pano A, Wheeler A, Paolini JF; RHAPSODY Investigators. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. N Engl J Med. 2021 Jan 7;384(1):31-41. doi: 10.1056/NEJMoa2027892. Epub 2020 Nov 16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	11-point NRS pain score	change in patient-reported pericarditis pain using an 11-point NRS from baseline to 8 weeks	8 weeks
Secondary	11-point NRS pain score	Pain score using 11-point NRS after 26 weeks of treatment	26 weeks
Secondary	Normalized CRP levels	Percentage of patients with normalized CRP levels at 26 weeks (for patients with CRP =1.0 mg/dL at baseline)	26 weeks
Secondary	Normalized CRP levels	Time to CRP normalization for patients with CRP =1.0 mg/dL at baseline	Over 26 weeks
Secondary	CRP change from baseline	CRP change from baseline	26 weeks
Secondary	pericarditis recurrence during the extension period (EP)	Percentage of patients with pericarditis recurrence during the extension period (EP)	26 weeks